AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.

PRNewsWire • 6 hours ago

Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication

AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.

Zacks Investment Research • Jun 2, 2026

Here's Why Amgen (AMGN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 1, 2026

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.

PRNewsWire • May 29, 2026

Ember LifeSciences announces new strategic investments boosting Series A to $27M

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN ) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.

PRNewsWire • May 27, 2026

This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

Most people think you can't time the market. That's nonsense.

Forbes • May 27, 2026

Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

Zacks Investment Research • May 27, 2026

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • May 26, 2026

AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

Zacks Investment Research • May 26, 2026

Amgen's Growth Engine Is Just Getting Started

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation. AMGN's pipeline strength is evident, with 16 drugs on track for blockbuster status and promising new assets like MariTide in obesity. At a forward P/E of 15.1 and 3% yield, AMGN offers an attractive blend of income and growth, justifying a continued ‘Buy' rating.

Seeking Alpha • May 26, 2026